MOESM5 of Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo

Adam Spivak, Erin Larragoite, McKenna Coletti, Amanda Macedo, Laura Martins, Alberto Bosque & Vicente Planelles
Additional file 5: Figure 4. Ruxolitinib-induced cytokine changes in PBMCs from aviremic HIV-1 infected donors. CD25 (IL2r), IL-5, and IL-13 concentrations were significantly decreased in PBMC cultures exposed to ruxolitinib + ingenol-3,20-dibenzoate compared to ingenol-3,20-dibenzoate alone. Ruxolitinib significantly reduced these cytokine concentrations in CD3/28 antibody-treated PBMC cultures as well, along with reduction in IL-10. Ruxolitinib did not decrease pro-inflammatory cytokines induced by CD3/28 antibody stimulation to the same degree as ingenol-stimulated cells (shown in Fig....
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.